Optibiotix Health Share Discussion Threads

[bobdown2] 13/9/2017 09:00

Someone is determined to undermine this news !!!

[judijudi] 13/9/2017 09:00

Why sell now?
Can never understand people's mentality

[riskybusiness1] 13/9/2017 08:46

One thing to note is the 2m in sales they have brought in from this strain within 2 years on the back of animal studies. A reminder to the potential revenues these companies can bring in pretty quickly. With Optis low cash burn you get the idea that when Optis up and running commercially the potential for a very profitable business is very real indeed.

[bobdown2] 13/9/2017 08:13

Let's hope so t.t. Children's illnesses always seem to be the worst..

[semper vigilans] 13/9/2017 07:59

I'm interested in a fit 20 year old......

[bobdown2] 13/9/2017 07:56

A fit young 20 year old...

[parob] 13/9/2017 07:54

-- The possibility of combining relevant assets to broaden the commercial offering and global reachIn the not too distant future, we could be looking at a pill that reduces your cholesterol and blood pressure AND improves your mental health. Who's not going to be interested in that!

[bobdown2] 13/9/2017 07:45

It looks a bit like a back burner r.n.s that smacks of future promise. But the new areas will look fantastic as they are developed and are we now begining to see the biome market place in its infancy...ps. Will some of these unexpected r.n.s statements stop some of the volatility caused by traders expecting to see Opti trading between certain ranges..

[judijudi] 13/9/2017 07:43

Another brick in the wall this morning
Good find last night Parob

[john henry] 13/9/2017 07:42

Moving into the pharma area, wow.

[owenmo] 13/9/2017 07:39

One day one of these will ignite things?

[owenmo] 13/9/2017 07:36

Plus, as ever, the kudos, not to mention the integrity of science, is the driving force here.Partners who are scientists first and foremost.

[bernieboy] 13/9/2017 07:36

Agreed bobdown and also the mention of animal health with the Bened tie up too.....as well as this bit which SOH has hinted at previously: the potential to address a range of mental and emotional health issues such as anxiety, depression, autism and Parkinson's. Wow its really hotting up around here!

[bobdown2] 13/9/2017 07:33

Apart from the new product fields there is the line global manufacturing partners...Opti look to be expanding at a rate of knots now..

[bernieboy] 13/9/2017 07:28

And a few Bened company numbers/details to go with that info:

Company Snapshot

Head count. 42
Patents. 32
Clinical Trials. 6
Trademarks. 21

Product variety. 10
Market. 10 countries
Shipment. 100,000+boxes in 2016
Global partners. 15

Their first product in this field was out in 2012 so they have good experience and also first mover advantage.....relatively small company but very significant tie up none the less......

[primal123] 13/9/2017 07:25

Roll on - you have no clue, can you tell me other companies in this field in Asia. "Bened Biomedical is the first psychobiotic brand to ever develop in Asia." Some people just want the big deals but SOH said he will get the RIGHT DEAL.

[parob] 13/9/2017 07:24

A move into psychobiotics with a company at the forefront - and already established sales channels for LP-LDL. What's not to like.



Mission

To develop best-of-breed psychobiotics which can effectively prevent and alleviate mental disorders for the global community.

We grow our business through a strong partner ecosystem focused on:

- Clinical studies, patents, trademarks, etc.
- Global cross-licensing and experience sharing
- Global manufacturing alliances
- Global sales and distribution network
- Strategic investment

Vision

To develop pharma-class probiotics which can effectively modulate human microbiome to prevent and treat diseases, with the following characteristics:

T rustable: evidence-based with clinical studies
E ffective: of high efficacy and stability
A ffordable: benefit the most people
P rotected: with strong IP portfolio

[john henry] 13/9/2017 07:21

Rollon my I suggest you read of the RNS several times and try really hard to understand the content.

[rollthedice] 13/9/2017 07:14

Diddly squat partner... surely they could have found a major partner for such an important region.

[shrewdmole] 13/9/2017 07:09

Very clever strategic tie up here.

Extg distribution and sales network in Asia.
We get to take their cognitive strain to thenUS and Europe!!

Can't be long before skinbio news now surely?

S

[bernieboy] 13/9/2017 07:07

This looks like a very decent partnership expanding Opti both into the psychobiotics field and for their own products into SE Asia, Taiwan, Korea and Japanese market. Impressive!

[someuwin] 13/9/2017 07:04

OptiBiotix Health plc

("OptiBiotix" or "the Company")



Strategic partnership with Bened Biomedical



OptiBiotix Health Plc (AIM: OPTI), a life sciences business developing compounds to tackle obesity, high cholesterol and diabetes, has signed a Memorandum of Understanding ("MoU") with Bened Biomedical Ltd., Taiwan ("Bened"). The MoU sets the framework for a strategic partnership to explore licensing and sales opportunities and the potential of combining relevant assets, over the next 12 months.



Bened Biomedical Co., Ltd., was founded in 2015 as a spin off from National Yang-Ming University ("NYMU") by Professor Tsai, Ying-Chieh. Bened is a leading probiotic research and marketing companies in Asia developing microbiome based products for neuropsychological, allergic, immunological, metabolic and aging-related disorders. In the past two years, its flagship psychobiotic PS128® products which help improve mental and emotional health, have been sold through both on-line and off-line channels in more than ten countries, generating revenues in the excess of US$2m.



The MoU provides a 12 month period to explore opportunities relating to OptiBiotix's cholesterol and blood pressure reducing LPLDL® strain and Bened's PS128®, a psychobiotic that has shown encouraging results in reducing anxiety and depression in animal studies.



This agreement includes:-



· The potential for Bened to commercialise OptiBiotix's LPLDL® strain in Taiwan, Japan, Korea, and South East Asia

· The potential for OptiBiotix to commercialise Bened's PS128 strain in Europe and the USA

· The possibility of combining relevant assets to broaden the commercial offering and global reach



For OptiBiotix this means:



· Widening OptiBiotix's probiotic portfolio into the area of psychobiotics

· Entering into the area of the "Microbiota-Gut-Brain Axis" where mounting evidence suggests that the microbiome helps shape neural development, brain biochemistry and behaviour

· Opening commercial routes into Taiwan, Japan, Korea and SE Asia for the Company's cholesterol and blood pressure reducing LPLDL® strain

· Gaining access to territories in the Asia Pacific region with a total probiotic retail value of $16.1 billion, of which supplements are $700 million. Japan being the third largest market for probiotic supplements with a predicted 8% growth by 2021 and the Taiwanese markets predicted a 27% growth by 2021



The two parties aim to enter definitive legal agreement on commercial and financial terms during the 12 month period. This is expected to create mutual value through royalty or asset payments. More information about the specific agreement will be provided in due course.



Market data from 'TRENDS, INNOVATIONS AND OPPORTUNITIES DRIVING THE GLOBAL PROBIOTICS MARKET' (Euromonitor International June 2017).



Stephen O'Hara, Chief Executive Officer of OptiBiotix, said: "We are pleased to announce this strategic partnership with Bened Biomedical and see a strong rationale for both companies to work together based on a complementary understanding of the science in different application areas of the microbiome. We are excited by recent advances in psychobiotics which have the potential to address a range of mental and emotional health issues such as anxiety, depression, autism and Parkinson's. We strongly believe Bened's scientific and commercial capabilities in psychobiotics creates potential for OptiBiotix to bring new products to new markets and extend both our product offering and global reach in the microbiome field to bring better science and better health to all."



Frankie Cheng, Chief Executive Officer of Bened Biomedical, said: "OptiBiotix operates in a very exciting and progressive area that has the potential to bring real health benefits. It has exciting products with strong science and clinical studies which we believe can be commercialised successfully through our distribution capability. We see mutual benefit in OptiBiotix's commercial advances in Europe and US as a way to bring our PS128® product to a wider audience."



For further information, please contact: